IMMUNOTHERAPY

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses treatment decisions for patients with melanoma.

With the arrival and incorporation into clinical practice of immunomodulatory drugs and proteasome inhibitor therapy, patients with multiple myeloma patients are achieving deep, durable responses and disease control, and are living longer

Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing immunotherapy and targeted therapy for patients with melanoma.

MK-3475, an investigational immunotherapy, has demonstrated an objective response rate (ORR) of up to 24% in patients with previously treated non-small cell lung cancer (NSCLC), according to interim results from a phase Ib expansion study.

Karl Lewis, MD, discusses new and emerging treatments for metastatic melanoma.

Roy S. Herbst, MD, PhD, discusses targeting PD-1 and PD-L1 when treating patients with lung cancer.

Jeffrey A. Sosman, MD, discusses how immunotherapies work in patients with melanoma or renal cancer.

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

The human epidermal growth factor receptors (known as the HER family) play a pivotal role in transmitting signals that regulate cell growth and survival.

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, discusses the background of the prophage G-200 vaccine for recurrent glioblastoma multiforme.

The efficacy of combining two immunotherapy agents will be assessed in a randomized, double-blind phase III study.

Julie R. Brahmer, MD, Associate Professor, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses patient response to immunotherapy.

Howard L. Kaufman, MD, says that the oncology community is in its infancy in terms of selecting and sequencing immunotherapies for patients with melanoma.

Catherine Bollard, MBChB, MD, from the Baylor College of Medicine, discusses T cells and TGF-beta in Hodgkin's lymphoma and Non-Hodgkin lymphoma.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Pazopanib was better tolerated with noninferior efficacy when compared to sunitinib as a treatment for patients with advanced renal cell carcinoma.

Elizabeth Mittendorf, MD, PhD, from the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer.

Renier J. Brentjens, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the potential efficacy of CAR-modified T cells for the treatment of solid tumors.

The investigational immunotherapy Allovectin (velimogene aliplasmid) failed to meet key endpoints in a phase III trial in patients with stage III/IV metastatic melanoma.

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, describes immunotherapy as one of the most exciting advances in cancer care.

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.

Silvia Novello, MD, PhD, from the University of Turin, Italy, gives an overview of immunotherapy and the targeting of the MAGE-A3 protein in lung cancer.

Lynn M. Schuchter, MD, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for recurrent glioblastoma multiforme.